临床药师参与1例药源性重度血小板减少症的病例分析  

Medicationanalysis of clinical pharmacists participating in one patient with severe drug-induced thrombocytopenia

作　　者：周庆秋[1] 吴云[2] ZHOU Qingqiu;WU Yun(Department of Pharmacy,Taian City Central Hospital,Taian 271000,China;Heart Center,Taian City Central Hospital,Taian 271000,China)

机构地区：[1]泰安市中心医院药学部,山东泰安271000 [2]泰安市中心医院心脏中心,山东泰安271000

出　　处：《药学研究》2018年第6期365-367,共3页Journal of Pharmaceutical Research

摘　　要：目的探讨急性心肌梗死患者经皮冠脉介入治疗术(PCI)后发生严重药源性血小板减少症(DITP)的相关药物。方法临床药师对该例患者的用药情况进行分析,协助制定药源性血小板减少症的对症治疗方案并全程实施药学监护。结果临床药师判定替罗非班为致血小板减少症的可疑药物。经对症治疗后,患者血小板逐渐恢复正常,病情缓解出院。结论临床药师参与药源性血小板减少症患者的治疗与监护,可减少不良反应的发生,保障患者的用药安全。Objective To investigate the related drugs of severe drug-induced thrombocytopenia in patients with acute myocardial infarction after percutaneous coronary intervention（ PCI）. Methods The typical cases participated by clinical pharmacist were shared and analyzed from three aspects of analyzation of drugs that may caused drug-induced thrombocytopenia,formulation of therapeutic regimen and implementation of pharmaceutical care. Results Tirofiban as a suspect drug for thrombocytopenia was identified.Platelets of the patient gradually returned to normal level with symptomatic treatment.The patient discharged after symptomatic remission.Conclusion Clinical pharmacists participated in the treatment and monitoring of patients with drug-induced thrombocytopenia,can reduce the occurrence of adverse reactions,to ensure the safety of patients.

关 键 词：药源性血小板减少症 临床药师 肝素 替罗非班 药学监护 

分 类 号：R969.3[医药卫生—药理学]